Amedisys (AMED) Tops Q1 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Total other expense, net: 3.84M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total other expense, net: 3.84M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q1 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $399.3 million versus the consensus estimate of $395.28 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, versus the consensus of $3.00. Amedisys sees FY2018 revenue of $1.6-1.64 million, versus the consensus of $1.63 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
